The medcomms man with a plan

I'm Dr Carl Owen

I'm a Founder

I'm a Scientist

I'm an Advocate

I'm an Investor

I'm a Gamer

Dr Carl Owen BSc MSc PhD

I’m also an introvert. And that’s my superpower.


I loved being a lab scientist but left academia to become a medical writer due to the crystal clear career path and because I wanted to settle down and have a family. It was the best decision I ever made. I started working as a medical writer in an office, which was an incredibly tough environment for an introvert like me. The commute sat in traffic. The visual and verbal distractions. The constant social interactions. I love talking to people and building personal relationships, but I’m no socialite. Open-plan offices drain my soul. It’s how I’m built.

Being a medical writer is incredible but despite it totally lending itself to independent working, my requests to work from home were always rejected. I don’t like being told what I can’t do. I was never one to conform or follow the rules. And this inspired me to build a company with an environment where people like me could flourish. A remote-working, flexible culture built on trust. Our people can choose what works best for them and their lives. How they get the work done is up to them.

This approach has been stupendously successful. My flagship company Word Monster became a 7-figure agency within 5 years. We’re now a team of 30+ working across the UK, Europe, USA and Australia… and growing. My design, communications management and 3D printing agencies all complement each other perfectly, collaborating under the Monster Medical Group.

Being a founder is difficult at times. It ain’t all sunshine and rainbows but I freakin’ love it. I’m not the typical entrepreneur seen in Hollywood movies. I don’t go to the gym for two hours before I start work every day. I don’t work evenings or weekends. Instead, I roll out of bed late, get work done around my homelife, and chill out often because I need heaps of time to unplug and recharge. I get my energy back from hanging out with my wonderful wife and three wild kids, playing tennis or immersing myself in games.

I’m always open to speaking with new people about business opportunities, science, work culture, investments and computer games. Get in touch if you fancy a chat.

Founder


My companies sit within the medical and healthcare markets. We provide consultancy services to the pharmaceutical industry to raise awareness of medicines and medical devices via education and promotion.

The Monster Medical companies

Scientist


As a Sport Scientist turned Molecular Physiologist, I earned my PhD researching a diabetes drug target called PTP1B. I discovered how targeting PTP1B in fat cells and the liver affects blood glucose levels. A terrific tale of blood, sweat and tears, earning me a scroll with Doctor of Philosophy in Biomedical Sciences written on it. It still sits on my shelf to this day.

Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and
Is a Minor Regulator of Glucose Homeostasis

Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress
Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis

Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis
Fenretinide Treatment Prevents Diet-Induced Obesity in Association With Major Alterations in Retinoid Homeostatic Gene Expression in Adipose, Liver, and Hypothalamus

Fenretinide Treatment Prevents Diet-Induced Obesity in Association With Major Alterations in Retinoid Homeostatic Gene Expression in Adipose, Liver, and Hypothalamus
Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice

Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice
Myeloid-cell protein tyrosine phosphatase-1B deficiency

Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide induced inflammation, hyperinsulinemia and endotoxemia through an IL-10 STAT3-dependent mechanism
Regulation of growth hormone induced JAK2 and mTOR signalling by hepatic protein

Regulation of growth hormone induced JAK2 and mTOR signalling by hepatic protein tyrosine phosphatase 1B

Advocate


Ultimate freedom, autonomy and trust sits at the heart of our companies. We live a life-first culture that offers the flexibility everyone needs to be able to spend quality time outside of work with friends and family. The way it should be. Come join the flexible-working revolution.

Investor


Being an agency founder doesn’t mean forgetting to take note of great work elsewhere. I invest in forward-thinking start-ups in the science and technology industries, including healthcare, pharmaceuticals, medical devices, communications, renewables, robotics and space. Together, we’re ready to take on the future.

The Monsters’ Den investment portfolio

Gamer


Gaming provides the zen I need to recharge and refocus. You’ll catch me playing Counter-Strike every Monday and Wednesday night – watch me on Twitch. Or hit me up if you fancy a co-op sesh.

Currently playing

Top classics

Join me

Carl with coffee